Systematic review & meta-analysis by DrHChaudhary et al @DaoudAnsaam @mmagrey1 showed that males w/ axSpA who were treated with biologics had ⬆️ BASDAI150 response & likely w/ ASDAS low dse activity vs. females w/axSpA Again, effect of gender differences @RheumNow #ACR24 abs599 https://t.co/2DPYC8exES

• https://x.com/RHEUMarampa/status/1857910937107186025/photo/1

Coming from somewhere where biosimilars are SOC for many years, I just find it wild how things are biosimilar wise in the US. Reflected by so many abstracts, including lots of oral presentations, essentially on showing biosimilars work. #ACR24 @RheumNow

How does #cardiovascular risk vary with #ACPA & #biologics in #RA? ⬆️BMI assoc with ⬆️MACE risk in ACPA+ pts In ACPA- pts, BMI inversely assoc with MACE risk among pts on biologics Further evidence to consider ACPA, BMI & MACE as part of RA management Ab0870 #ACR24 @RheumNow https://t.co/UkkC146DWS

• https://x.com/DrMiniDey/status/1857893908073820672/photo/1

Stone et al. Phase 3 RCT B-cell depletion with CD19 targeting agent Inebilizumab in IgG4-RD. HR 0.13 (0.06, 0.28) for flare. @RheumNow #ACR24 Abstr#0775 https://t.co/Kd4Xmoc5e6 https://t.co/Al6gOA1F8K

• A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of I…
• https://x.com/RichardPAConway/status/1857866477065416868/photo/1

Medication-assisted weight loss has boomed in recent yrs. How does weight loss affect disease activity & PROs in RMDs? ≥5% weight loss, after taking a med, led to better disease activity & QoL Data may inform RCTs to explore effect of these meds in RMDs Ab0845 #ACR24 @RheumNow

Results from MANDARA- #EGPA pts treated with benralizumab or mepolizumab Eosinophil-targeting biologics rapidly control airway- & non-airway-related manifestations Few pts had worsening of disease that progressed to organ damage over 52W Ab0828 #ACR24 @RheumNow https://t.co/hIn9iyNVWQ

• https://x.com/DrMiniDey/status/1857869245658620106/photo/1

Ab#0458 #ACR24 10 year outcomes of 176 patients with seroneg RA 32 pts (18%) had change in dx - SpA (11), seropos RA (6), OA (5), crystal (3), CTD (3), Ifn-related/paraneopl/RS3PE, sarcoid (1) 40 (23%) had drug-free remission 30 (17%) started b/tsDMARD @RheumNow

Langford et al. Abatacept NOT effective in GPA in ABROGATE RCT. 65 patients. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point. @RheumNow #ACR24 Abstr#0823 https://t.co/yRFZ2diJFF https://t.co/LgXkPnDArE

• A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treat…
• https://x.com/RichardPAConway/status/1857848106349412762/photo/1

Briefly highlighting this poster, always looking for a non-Georg Schett CAR-T study to see if their results replicate All 10 pts in this one had a "complete humoral response," normalizing antibodies & experiencing long term drug-free remission #ACR24 @RheumNow Abstr#0673 https://t.co/pjOjRnJVhO

• https://x.com/EBRheum/status/1857839298227077451/photo/1

A cohort of 9 patients with Anti-MDA5 DM with RPILD who was treated with combination of RTX, JAKi, and GCS had significantly bettery survival compared to historical cohort in this abstract! #ACR24 @RheumNow https://t.co/2t8xcYJ3UV

• https://x.com/MartinezZayasMd/status/1857838587611406427/photo/1

This is likely an oversimplification, but I've been looking for exactly this diagram Inhibiting various TYKs/JAKs corresponds to various downstream cytokine inhibition @EricFMorand does it make sense to see this as anifrolumab+ustekinumab? No? @rheumnow #ACR24 Abstr#0662 https://t.co/thti6s5TR3

• https://x.com/EBRheum/status/1857836781628174735/photo/1
• https://x.com/EBRheum/status/1857836781628174735/photo/1

FDA has given FDA Breakthrough Therapy designation to Nipocalimab for treatment of adults w/ moderate-to-severe Sjögren’s disease. NIPO is an Ab to neonatal Fc receptor (FcRn), & was tested and shown effective in Sjog in the Phase 2 DAHLIAS study - a plenary presentation at… https://t.co/aQDp7iPKXD https://t.co/hJ8fe6JwxC

De Lorenzis et al. MMF in LcSSc. Target Trial Emulation. 1435 patients. Incidence vasodilator treatment escalation over 41 months, 1/100py in MMF vs 7.3/100py in controls. @RheumNow #ACR24 Abstr#0688 https://t.co/D3qTUHyIIc https://t.co/6azvaS0ElL

• Mycophenolate Mofetil Treatment in Limited Cutaneous Systemic Sclerosis Reduces…
• https://x.com/RichardPAConway/status/1857826212040573293/photo/1